ID Consult

Kawasaki disease: New info to enhance our index of suspicion


 

Most U.S. mainland pediatric practitioners will see only one or two cases of Kawasaki disease (KD) in their careers, but no one wants to miss even one case.

Making the diagnosis as early as possible is important to reduce the chance of sequelae, particularly the coronary artery aneurysms that will eventually lead to 5% of overall acute coronary syndromes in adults. And because there is no “KD test,” we must rely on a constellation of clinical and laboratory findings to develop over a period of days in order to cobble together a diagnosis of KD, or sometimes incomplete KD. And there are some new data that complicate this. Despite the recently updated 2017 guideline,1 most cases end up being confirmed and managed by regional “experts.” But nearly all of the approximately 6,000 KD cases/year in U.S. children younger than 5 years old start out with one or more primary care, urgent care, or ED visits.

This means that every clinician in the trenches not only needs a high index of suspicion but also needs to be at least a partial expert, too. What raises our index of suspicion? Classic data tell us we need 5 consecutive days of fever plus four or five other principal clinical findings for a KD diagnosis. The principal findings are:

1. Eyes: Bilateral bulbar nonexudative conjunctival injection.

2. Mouth: Erythema of oral/pharyngeal mucosa or cracked lips or strawberry tongue or oral mucositis.

3. Rash.

4. Hands or feet findings: Swelling/erythema or later periungual desquamation.

5. Cervical adenopathy greater than 1.4 cm, usually unilateral.

Pages

Recommended Reading

FDA seeks comments on pediatric HIV product development
MDedge Pediatrics
ADHD, asthma Rxs up
MDedge Pediatrics
Persistent providers sway parents to accept HPV vaccination
MDedge Pediatrics
Which infants with invasive bacterial infections are at risk for adverse outcomes?
MDedge Pediatrics
Simple QI intervention helped improve HPV vaccination rates
MDedge Pediatrics
FDA: PrEP indication updated to include adolescents at risk of HIV infection
MDedge Pediatrics
The double-edged sword
MDedge Pediatrics
HBV birth dose predicts vaccine adherence
MDedge Pediatrics
NIH launches early Ebola treatment trial
MDedge Pediatrics
MDedge Daily News: Keeping patients summer safe
MDedge Pediatrics